Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - USD ($) $ in Millions	12 Months Ended			72 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 12,172.9	$ 16,071.7	$ 8,497.1
Teva
Disaggregation of Revenue [Line Items]
Revenues				$ 120.0
Teva | Reduction of R&D expense | Reimbursement of R&D expenses
Disaggregation of Revenue [Line Items]
Revenues		42.4	109.4
Teva | Other operating income | Amounts recognized in connection with up-front payments received
Disaggregation of Revenue [Line Items]
Revenues	$ 33.3	$ 26.2	$ 47.2